Mediforum’s Myungminwon was shown to reverse the effects of cognitive decline in a patient suffering from Alzheimer’s disease. Improvements were seen in various clinical examinations, including MMSE, CERAD, ADL, NPI, HAM-D and dementia rating scales.
LOS ANGELES, CA, December 20, 2021 /24-7PressRelease/ — Mediforum’s Myungminwon was tested in a clinical trial with an Alzheimer’s patient with mild cognitive impairment. Over the course of a 12 month study, the patient’s mental state and cognitive skills were measured at set intervals to determine the effectiveness of the Myungminwon herbal supplement. According to earlier studies on Arch Neurol., patients diagnosed with Alzheimer’s disease on averaged had MMSE scores declining about 4 points on an annualized basis. MMSE, which stands for Mini Mental State Examination, is a 30 test questionnaire used extensively in clinical and research settings to measure cognitive impairment involving 8 different aspects of mental cognition, including time and place of the exam, arithmetic, vocabulary, language use, language comprehension, and basic motor skills. Scores lower than 24 out of 30 indicate cognitive impairment. The test patient began the assessment with a score of 21, indicating mild cognitive impairment. At the end of the 12 month study, the patient registered improvements 5 out of 8 categories for a final MMSE score of 27, which is solidly within the range of normal cognition.
Other clinical examinations took place, including CERAD, ADL, NPI, HAM-D and the following dementia rating scales, GDS, CDR and CDR-SB. CERAD, The Consortium to Establish a Registry for Alzheimer’s Disease, us a neuropsychological battery developed to assess the cognitive change over time for the diagnosis and management of Alzheimer’s disease. According to studies published in Alzheimer Dis Assoc Disord., CERAD scores for individuals diagnosed with Alzheimer’s disease declined on average by 6 points on an annualized basis. The patient’s score before treatment began was 31 out of 100 for CERAD 1 and 33 out of 111 for CERAD 2. After 12 months, the test patient scored 60 out of 100 for CERAD 1 and 62 out of 111 for CERAD 2, which is within the normal range.
ADL, Activities of Daily Living, is an exam determining impairment in the ability of the patient to conduct activities of daily living within a society. S-ADL is the Seoul variant of the test, while the I-ADL is the Instrumental ADL for more complex tasks necessary to integrate within a community. Basic ADLs include dressing, eating, grooming, using the bathroom and mobility, whereas I-ADLs include cooking and meal preparation, medical management, managing finances and transportation. Lower scores are indicative of better functioning. The patient began with S-ADL of 1 out of 24 and I-ADL of 10 out of 45. At the end of the 12 month period, the patient scored 0 out of 24 and 5 out of 45 respectively on the S-ADL and I-ADL exams.
HAM-D is the Hamilton Depression rating scale, and simply assesses the symptoms of depression in a patient. Scores of 10 to 13 indicate mild depression, 14 to 17 indicates moderate depression and 18 or greater indicates severe depression. The patient began with an assessed score of 15 and improved to a score of 11 at the end of the 12 month test period.
GDS, Global Deterioration Scale, CDR, Clinical Dementia Rating, and CDR-SB, Clinical Dementia Rating Sum of Boxes, are all assessment instruments used to determine the severity of dementia in a patient. The patient began with scores of 3, 0.5 and 2 for GDS, CDR and CDR-SB respectively and concluded the 12 month evaluation with scores of 3, 0.5 and 1.
Blood tests were administered and analyzed during the study with no measureable negative consequences from taking Myungminwon. Brain MRI was done before and after the test period to determine any abnormalities, the initial image showed moderate brain atrophy but the follow up image showed reduced brain atrophy.
The test was conducted by the Department of Cardiology and Neurology of Korean Medicine at the College of Korean Medicine, Daejeon University in conjunction with the Clinical Trial Center at the Daejeon Korean Medicine Hospital of Daejeon University and the Myungmin Korean Medicine Clinic. The original case report is available in The Journal of Internal Korean Medicine 2021, 42(5): 1082-1093.
Mediforum is a bio-tech firm out of Seoul, Korea that is leading the race to find a treatment for Alzheimer’s dementia with a focus on producing safe and effective drugs and supplements without the harmful side-effects common in drugs today. The company is the first to reach the 3rd phase clinical trial in Korea for the treatment of Alzheimer’s dementia.
Myungmin is available in four different formulations with varying strengths and forms for ease of consumption.
Myungminhwan is a specially formulated herbal supplement that is prepared in another traditional form of small bead-size chewable balls.
Myungmindan is prepared in a distinctly traditional way as to maximize the experience of its unique aroma and taste. The supplement is made in a marble-size chewable ball which allows for easy chewing and consumption.
Myungminwon is a liquid based herbal supplement that has the highest concentration of the active natural compounds that work to fight beta amyloid plaque, stimulate neurogenesis, improve overall brain health while also aiding in enhancing memory and concentration. The liquid form allows for easier consumption for individuals who suffer from dysphagia or have difficulty with swallowing.
Myungminwon Gold is the most premium formulation in the Myungmin Series. In addition to all the benefits of Myungminwon, it also includes cervi parvum comu extract which greatly boosts strength, endurance, and improves your immune system.
Mediforum has partnered with the Parkinson’s Disease Association in Korea and conducted studies showing improvements in quality of life for individuals suffering from Parkinson’s disease. Patients exhibited a positive improvement in tremor of the limbs, motor skills, an increased appetite and mental acuity.
Myungmin series was recently featured on RadioKorea as a treatment for multiple forms of dementia, Alzheimer’s and Parkinson’s disease.
Mediforum was born out of researchers working at leading universities in Korea in the field of medicine and traditional medicine. Their mission has been one of producing effective and safe supplements and drugs utilitizing naturally sourced compounds and testing them vigorously utilizing western clinical trial methodology. Having seen the long list of side-effects associated with the vast majority of intervention strategies for Alzheimer’s and cancer, Mediforum is leading the way to produce supplements and drugs to improve the quality of life for those suffering from such conditions. The company also offers a vast lineup of rapid PCR diagnostics test kits for HPV and STDs and other genetic biomarkers and conditions.
For the original version of this press release, please visit 24-7PressRelease.com here